表紙
市場調查報告書

焦點市場分析:神經內分泌腫瘤 (NET)

Market Spotlight: Neuroendocrine tumors (NET)

出版商 Datamonitor Healthcare 商品編碼 603950
出版日期 內容資訊 英文 45 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
焦點市場分析:神經內分泌腫瘤 (NET) Market Spotlight: Neuroendocrine tumors (NET)
出版日期: 2019年12月31日內容資訊: 英文 45 Pages
簡介

全球神經內分泌腫瘤 (NET)的發病數,預測將從2017年的約486,500件,增加到2026年586,100件。

本報告提供全球神經內分泌腫瘤 (NET) 治療藥市場相關調查分析,提供主要的上市·開發平台藥物,最近的趨勢和分析師的見解,臨床實驗,成功的概率,今後趨勢與法規趨勢,專利資訊,10年的發病率預測,許可證·收購交易,收益預測相關的系統性資訊。

概要

要點

疾病的背景

  • 亞型

治療

  • 手術
  • 肝動脈栓塞術
  • 生長抑制素類似體
  • 干擾素-Alpha (IFN-alpha)
  • 化療
  • 放射線治療
  • 標靶治療
  • 緩和療法

流行病學

上市藥

開發平台藥物

最近的趨勢和分析師的見解

  • TBR-760
  • Qarziba

今後趨勢

主要的法規趨勢

成功的概率

許可證·資產收購交易

母專利

商機

臨床實驗形勢

  • 贊助商:各狀況
  • 贊助商:不同階段

參考文獻

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0184311

This Market Spotlight report covers the Neuroendocrine Tumors market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, probability of success, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Datamonitor Healthcare estimates that in 2017, there were approximately 486,500 incident cases of neuroendocrine tumors (NETs) worldwide, and forecasts that number to increase to 586,100 incident cases by 2026. Worldwide, the majority of NETs in 2017 were malignant carcinoid tumors or neuroendocrine carcinomas. The approved drugs in the NETs space focus on targets such as norepinephrine (noradrenaline), radiopharmaceutical, mammalian target of rapamycin/mTORC, tyrosine hydroxylase, somatostatin receptors, FMS-like tyrosine kinase 3, KIT/c-KIT, platelet-derived growth factor receptor, VEGF receptor, ganglioside GD2, and tryptophan hydroxylase. These drugs are predominantly administered via the oral, intravenous, and subcutaneous routes, while one product is available in an intramuscular formulation.

The majority of industry-sponsored drugs in active clinical development for NETs are in Phase I, with only one product in Phase III.

Therapies in the pipeline for NETs focus on a wide variety of targets. The largest proportion of these therapies are administered intravenously, with the remainder being oral, subcutaneous, intranasal, and intratumoral formulations.

The only high-impact upcoming event in the NETs space is topline Phase III trial results for sulfatinib. The overall likelihood of approval of a Phase I solid tumors asset is 5.6%, and the average probability a drug advances from Phase III is 40%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.3 years in the overall oncology space.

There have been only seven licensing and asset acquisition deals involving NETs drugs during 2014-19. The $115m exclusive licensing agreement signed in November 2017 between NanoCarrier and VBL Therapeutics for the development, commercialization, and supply of VB-111 (ofranergene obadenovec) in Japan was the only deal with a disclosed value.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for NETs have been in the early and midphases of development, with 77% of trials in Phase I-II, and only 23% in Phase III-IV.

The US has a substantial lead in the number of NETs clinical trials globally. The UK leads the major EU markets, while China has the top spot in Asia.

Novartis has the highest number of completed clinical trials for NETs, with 17 trials.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Surgery
  • Hepatic artery embolization
  • Somatostatin analogs
  • Interferon-alpha (IFN-alpha)
  • Chemotherapy
  • Radiation therapy
  • Targeted therapy
  • Palliative care

EPIDEMIOLOGY

  • Incidence methodology
  • Disease definition
  • Prevalence methodology

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • TBR-760 for NETs (January 3, 2019)
  • Qarziba for NETs (June 2, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • University of Iowa PET Center Earns NME Approval

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of NETs, 2017-26
  • Figure 2: Incident cases of NETs, by tumor type, 2017
  • Figure 3: Overview of pipeline drugs for NETs in the US
  • Figure 4: Pipeline drugs for NETs, by company
  • Figure 5: Pipeline drugs for NETs, by drug type
  • Figure 6: Pipeline drugs for NETs, by classification
  • Figure 7: Qarziba for NETs (June 2, 2018): Phase III - HR-NBL-1 (1.5) (EU)
  • Figure 8: Key upcoming events in NETs
  • Figure 9: Probability of success in the NETs pipeline
  • Figure 10: Licensing and asset acquisition deals in NETs, 2014-19
  • Figure 11: Parent patents in NETs
  • Figure 12: Clinical trials in NETs
  • Figure 13: Top 10 drugs for clinical trials in NETs
  • Figure 14: Top 10 companies for clinical trials in NETs
  • Figure 15: Trial locations in NETs
  • Figure 16: NETs trials status
  • Figure 17: NETs trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of NETs, 2017-26
  • Table 2: Five-year prevalent cases of NETs, 2017-26
  • Table 3: Marketed drugs for NETs
  • Table 4: Pipeline drugs for NETs in the US
  • Table 5: TBR-760 for NETs (January 3, 2019)
  • Table 6: Qarziba for NETs (June 2, 2018)
  • Table 7: Historical global sales, by drug ($m), 2014-18
  • Table 8: Forecasted global sales, by drug ($m), 2019-23
Back to Top